JPS6047244B2 - 薬剤 - Google Patents

薬剤

Info

Publication number
JPS6047244B2
JPS6047244B2 JP52000499A JP49977A JPS6047244B2 JP S6047244 B2 JPS6047244 B2 JP S6047244B2 JP 52000499 A JP52000499 A JP 52000499A JP 49977 A JP49977 A JP 49977A JP S6047244 B2 JPS6047244 B2 JP S6047244B2
Authority
JP
Japan
Prior art keywords
eye
trh
eye drops
day
cataract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP52000499A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5386009A (en
Inventor
浩臣 小野
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Priority to JP52000499A priority Critical patent/JPS6047244B2/ja
Priority to US05/865,722 priority patent/US4150120A/en
Priority to GB54285/77A priority patent/GB1596180A/en
Priority to DE19782800108 priority patent/DE2800108A1/de
Priority to NL7800065A priority patent/NL7800065A/xx
Priority to FR7800169A priority patent/FR2376664A1/fr
Publication of JPS5386009A publication Critical patent/JPS5386009A/ja
Publication of JPS6047244B2 publication Critical patent/JPS6047244B2/ja
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/066—TRH, thyroliberin, thyrotropin releasing hormone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C07K5/0825—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp and Glp-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP52000499A 1977-01-05 1977-01-05 薬剤 Expired JPS6047244B2 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP52000499A JPS6047244B2 (ja) 1977-01-05 1977-01-05 薬剤
US05/865,722 US4150120A (en) 1977-01-05 1977-12-29 Ophthalmic
GB54285/77A GB1596180A (en) 1977-01-05 1977-12-30 Ophthalmic composition
DE19782800108 DE2800108A1 (de) 1977-01-05 1978-01-03 Mittel zur behandlung von augenkrankheiten
NL7800065A NL7800065A (nl) 1977-01-05 1978-01-03 Preparaat voor het behandelen van oogziekten.
FR7800169A FR2376664A1 (fr) 1977-01-05 1978-01-04 Derive l-prolinamide et son utilisation comme moyen therapeutique pour le traitement des maladies des yeux

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP52000499A JPS6047244B2 (ja) 1977-01-05 1977-01-05 薬剤

Publications (2)

Publication Number Publication Date
JPS5386009A JPS5386009A (en) 1978-07-29
JPS6047244B2 true JPS6047244B2 (ja) 1985-10-21

Family

ID=11475440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52000499A Expired JPS6047244B2 (ja) 1977-01-05 1977-01-05 薬剤

Country Status (6)

Country Link
US (1) US4150120A (US08063081-20111122-C00044.png)
JP (1) JPS6047244B2 (US08063081-20111122-C00044.png)
DE (1) DE2800108A1 (US08063081-20111122-C00044.png)
FR (1) FR2376664A1 (US08063081-20111122-C00044.png)
GB (1) GB1596180A (US08063081-20111122-C00044.png)
NL (1) NL7800065A (US08063081-20111122-C00044.png)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4665089A (en) * 1985-03-21 1987-05-12 Massachusetts Institute Of Technology Process for preventing or reversing cataract formation using protein modification reagents
CN1011118B (zh) * 1986-06-13 1991-01-09 天津医学院附属医院 治疗白内障的眼药水的制药方法
EP3592377A4 (en) 2017-03-09 2021-02-17 Diamedica Inc. DOSAGE FORMS OF TISSUE KALLIKREIN 1

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3746697A (en) * 1969-09-19 1973-07-17 K Folkers Tripeptide having the activity of the thyrotropin releasing hormone
DE2410821A1 (de) * 1974-03-07 1975-09-18 Hoechst Ag Pharmazeutische kombinationspraeparate mit psychotroper wirkung und verfahren zu ihrer herstellung
US3932623A (en) * 1974-06-18 1976-01-13 Wilson Ian C Method of treating schizophrenia
JPS51118841A (en) * 1975-04-03 1976-10-19 Takeda Chem Ind Ltd A drug for improving and treating clouding of consciousness
AU504840B2 (en) * 1975-09-09 1979-11-01 Takeda Chemical Industries Ltd Medicinal compositions

Also Published As

Publication number Publication date
US4150120A (en) 1979-04-17
GB1596180A (en) 1981-08-19
JPS5386009A (en) 1978-07-29
NL7800065A (nl) 1978-07-07
DE2800108A1 (de) 1978-07-13
FR2376664B1 (US08063081-20111122-C00044.png) 1982-10-15
FR2376664A1 (fr) 1978-08-04

Similar Documents

Publication Publication Date Title
BERNSTEIN et al. Steroid-induced elevation of intraocular pressure
RU2572707C2 (ru) Глазные капли с дифлупреднатом для лечения отека желтого пятна
JPS62501002A (ja) 高い眼圧の防止法、緑内障の処置及び高眼圧の処置
JP7378781B2 (ja) 脳神経の薬理学的な経皮活性化による神経変性障害に関連する症状の治療
KR20150038311A (ko) 눈 질병 및 질환을 위한 조성물 및 치료
Bartlett et al. Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis
JPH0368006B2 (US08063081-20111122-C00044.png)
EP4226924A1 (en) Use of penehyclidine in treatment or prevention of vision-impairing eye diseases
US4870106A (en) Oculistics pharmaceutical composition for cataract treatment
JPS6061526A (ja) 眼内出血，近視性脈絡網膜ジストロフイ−，先天性網膜ジストロフイ−，網膜火傷の治療用及びレ−ザ−凝固における損傷防止用網膜保護剤
Lewis et al. Comparison of plain with pH-adjusted bupivacaine with hyaluronidase for peribulbar block
JPS6047244B2 (ja) 薬剤
Glasser et al. Ocular jellyfish stings
CN1239161C (zh) 可用于治疗干眼疾病的类固醇
CN109200016A (zh) 一种苄达赖氨酸滴眼液及其制备方法与用途
RU2345740C1 (ru) Способ лечения дистрофических заболеваний глаз грязелечебным средством "реликт-05"
US20040259844A1 (en) Method and composition for preventing, reducing and reversing ocular ischemic neuronal damage
TW201010694A (en) Compounds useful for the prevention or treatment of accommodative asthenopia
Wagih et al. Recurrent chalazia revealing an ocular rosacea in a child
US20140274985A1 (en) Systemic administration of androgen in treating dry eye syndrome
WO2022259132A1 (en) Pyrazolone compounds for use in degenerative retinal diseases
Moore 8 Chapter Anticholinergic Agents (Parasympatholytics)
TW202135745A (zh) 黃體激素組合
CN118284425A (zh) 丙谷二肽的新用途和包含丙谷二肽的眼用组合物
King JR Experience with newer corticosteroid hormones in eye diseases